LT3609486T - Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui - Google Patents

Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui

Info

Publication number
LT3609486T
LT3609486T LTEPPCT/EP2018/059295T LT18059295T LT3609486T LT 3609486 T LT3609486 T LT 3609486T LT 18059295 T LT18059295 T LT 18059295T LT 3609486 T LT3609486 T LT 3609486T
Authority
LT
Lithuania
Prior art keywords
sarpogrelate
mammals
treatment
heart diseases
heart
Prior art date
Application number
LTEPPCT/EP2018/059295T
Other languages
English (en)
Inventor
Estelle AYME-DIETRICH
Jérôme GUYONNET
Roland LAWSON
Luc Maroteaux
Laurent MONASSIER
Original Assignee
Ceva Santé Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Santé Animale filed Critical Ceva Santé Animale
Publication of LT3609486T publication Critical patent/LT3609486T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/EP2018/059295T 2017-04-11 2018-04-11 Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui LT3609486T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17165863 2017-04-11
EP17180011 2017-07-06
PCT/EP2018/059295 WO2018189246A1 (en) 2017-04-11 2018-04-11 Method for the treatment of heart disease in mammals

Publications (1)

Publication Number Publication Date
LT3609486T true LT3609486T (lt) 2021-10-11

Family

ID=61913190

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/059295T LT3609486T (lt) 2017-04-11 2018-04-11 Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui

Country Status (13)

Country Link
US (1) US11116741B2 (lt)
EP (1) EP3609486B1 (lt)
JP (1) JP7148545B2 (lt)
CN (1) CN110913846B (lt)
AU (1) AU2018253371B2 (lt)
BR (1) BR112019021344A2 (lt)
CA (1) CA3059512A1 (lt)
DK (1) DK3609486T3 (lt)
ES (1) ES2886045T3 (lt)
HU (1) HUE055319T2 (lt)
LT (1) LT3609486T (lt)
PL (1) PL3609486T3 (lt)
WO (1) WO2018189246A1 (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539760A (ja) * 2021-10-27 2024-10-30 メディテイク カンパニーリミテッド アンジオテンシン受容体拮抗薬およびｓｇｌｔ２阻害剤を含む複合組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
JP2008208122A (ja) * 2007-02-02 2008-09-11 Mitsubishi Tanabe Pharma Corp 肥満の予防及び／又は治療薬
GB0715047D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel Compounds
CN104619345A (zh) * 2012-05-18 2015-05-13 罗达制药有限公司 液体制剂
AU2013361340A1 (en) * 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
WO2016121738A1 (ja) * 2015-01-27 2016-08-04 国立大学法人山梨大学 シロスタゾールの薬効評価方法

Also Published As

Publication number Publication date
JP2020513028A (ja) 2020-04-30
JP7148545B2 (ja) 2022-10-05
EP3609486A1 (en) 2020-02-19
EP3609486B1 (en) 2021-06-02
ES2886045T3 (es) 2021-12-16
CN110913846B (zh) 2023-04-04
CA3059512A1 (en) 2018-10-18
US20200297685A1 (en) 2020-09-24
WO2018189246A1 (en) 2018-10-18
HUE055319T2 (hu) 2021-11-29
BR112019021344A2 (pt) 2020-06-16
AU2018253371A1 (en) 2019-10-31
DK3609486T3 (da) 2021-08-16
US11116741B2 (en) 2021-09-14
PL3609486T3 (pl) 2021-11-29
CN110913846A (zh) 2020-03-24
AU2018253371B2 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
IL272300A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
IL251530B (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
IL269083A (en) Methods for preventing and treating heart disease
EP3723692A4 (en) MEDICAL ASSISTANT
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
LT3592355T (lt) Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL280638A (en) Adipose tissue treatment
SI3565592T1 (sl) Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
IL270900A (en) Treatment of cutaneous disorders
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
LT3458045T (lt) Ebselenas, skirtas naudoti menjero ligos gydymui
IL280968A (en) Combination therapy
EP4069438C0 (en) SKIN TREATMENT SYSTEM
EP3856207A4 (en) TREATMENT PROCESSES
IL259381B (en) Mirabegron for the treatment of retinal diseases